VR
Verano Holdings Corp
VRNO · OTC
$6.18 +3.18% (+$0.19)
1M -0.99%
Market Cap $442.8M
P/E Ratio -
Div. Yield -
ROE 35.22%
Bulios Fair Price
$4.6
25.6% downside
Current Price
$6.18
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VRNO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/B 0.65x
EV/EBITDA 5.05x
P/FCF 9.77x
Growth
9 /100
Declining Book val. growth 19.38%
Rev. growth 1.68%
FCF growth N/A
Profitability
38 /100
Moderate Op. margin 6.45%
Gross margin 45.76%
FCF margin 5.35%
Quality
14 /100
Poor ROA 15.31%
ROIC 4.26%
Asset turnover 0.50x
Debt
44 /100
Moderate Int. coverage 0.77x
Debt/Equity 0.73x
Net debt/EBITDA 2.43x
Stability
41 /100
Moderate EPS volatility 123.44%
Beta 1.42x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VRNO
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
George Archos
Employees
3,800
Headquarters
Chicago
Upcoming events
04 NOV
Earnings
Upcoming earnings report